Inhibitory Effect of Piracetam on Platelet-rich Thrombus Formation in an Animal Model

Summary

Intravenous administration of piracetam to hamsters reduced the formation of a platelet-rich venous thrombus induced by a standardised crush injury, in a dose-dependent fashion with an IC₅₀ of 68 ± 8 mg/kg. 200 mg/kg piracetam also significantly reduced in vivo thrombus formation in rats. However, in vitro aggregation of rat platelets was only inhibited with piracetam-concentrations at least 10-fold higher than plasma concentrations (6.2 ± 1.1 mM) obtained in the treated animals. No effects were seen on clotting tests.

In vitro human platelet aggregation, induced by a variety of agonists, was inhibited by piracetam, with IC₅₀’s of 25-60 mM. The broad inhibition spectrum could be explained by the capacity of piracetam to prevent fibrinogen binding to activated human platelets. Ex vivo aggregations and bleeding times were only minimally affected after administration of 400 mg/kg piracetam i.v. to healthy male volunteers, resulting in peak plasma levels of 5.8 ± 0.3 mM.

A possible antiplatelet effect of piracetam could be due to the documented beneficial effect on red blood cell deformability leading to a putative reduction of ADP release by damaged erythrocytes. However similarly high concentrations were needed to prevent stirring-induced “spontaneous” platelet aggregation in human whole blood.

It is concluded that the observed antithrombotic action of piracetam cannot satisfactorily be explained by an isolated direct effect on platelets. An additional influence of piracetam on the rheology of the circulating blood and/or on the vessel wall itself must therefore be taken into consideration.

• References

• 1 Guirgea C. Piracetam: nootropic pharmacology of neurointegrative activity.. Curr Developm Psychopharmacol 1976; 3: 222-73.
• 2 Peuvot J, Schank A, Deleers M, Brasseur R. Piracetam induced changes to membrane physical properties. A combined approach by ³¹P nuclear magnetic resonance and conformational analysis.. Biochem Pharmacol 1995; 50: 1129-34.
• 3 Müller WE, Koch S, Scheuer K, Rostock A, Bartsch R. Effects of piracetam on membrane fluidity in the aged mouse, rat and human brain.. Biochem Pharmacol 1998; 53: 135-40.
• 4 Grotemeyer KH, Hofferberth B, Hirschberg M. Normalization of hyper-reactive thrombocytes in patients with TIA by piracetam?. Nervenarzt 1986; 57: 180-3.
• 5 Grekas D, Alivanis P, Karamouzis M, Pyrpasopoulos M. Piracetam as a potent inhibitor of plasma thromboxane B2 during hemodialysis.. Nephron 1989; 52: 372-3.
• 6 Nalbandian RM, Henry RL, Burek CL, Diglio CA, Goldman AI, Taylor GW, Hoffman WH. Diminished adherence of sickle erythrocytes to cultured vascular endothelium by piracetam.. Am J Hematol 1983; 15: 147-51.
• 7 Costa FF, Zago MA, Bothura C. Effects of piracetam and iodoacetamide on erythrocyte sickling.. Lancet 1979; ii: 1302.
• 8 Bick RL, Skondria V, Nix K. Prophylaxis of sickle-cell vaso-active crises with oral piracetam.. Blood 1981; 58 (Suppl. 01) 56a (abstr).
• 9 Moriau M, Crasborn L, Lavenne-Pardonge E, von Frenckell R, Col-Debeys C. Platelet anti-aggregant and rheological properties of piracetam. A pharmacological study in normal subjects.. Arzneim Forsch/Drug Res 1993; 43: 110-8.
• 10 Bick RL. In vivo platelet inhibition by piracetam.. Lancet 1979; ii: 752-3.
• 11 Sallier AC, Delaere A. ADR Profile of piracetam.. Post-marketing surveil-lance review of data collected through spontaneous reporting till December 1994. UCB Internal report, 1995.
• 12 Stockmans F, Deckmyn H, Gruwez J, Vermylen J, Acland R. Continuous quantitative monitoring of mural platelet-dependent, thrombus kinetics in the crushed rat femoral vein.. Thromb Haemost 1991; 65: 425-31.
• 13 Imura Y, Stassen JM, Collen D. Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model.. J Exp Pharmacol Ther 1992; 261: 895-8.
• 14 Imura Y, Stassen JM, Vreys I, Lesaffre E, Gold HK, Collen D. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor in a hamster femoral vein platelet-rich thrombosis model.. Thromb Haemost 1992; 68: 336-40.
• 15 Stockmans F, Hoet B, Deckmyn H, Gruwez J, Boeckx W, Acland R, Vermylen J. R68070, a combined thromboxane synthase and receptor blocker, reduces thrombus formation in rats.. Thromb Haemost 1989; 62: 169A.
• 16 Imura Y, Stassen JM, Bunting S, Stockmans F, Collen D. Antithrombotic properties of L-cysteine, N-(mercapto-acetyl)-D-Tyr-Arg-Gly-Asp-sulf-oxide (G4120) in a hamster, platelet-rich femoral vein thrombosis model.. Blood 1992; 80: 1247-53.
• 17 Deckmyn H, Stassen JM, Vreys I, Van Houtte E, Sawyer R, Vermylen J. Calin from Hirudo medicinalis, an inhibitor of platelet adhesion to collagen, prevents platelet-rich thrombosis in hamsters.. Blood 1995; 85: 712-9.
• 18 Stassen JM, Lambeir AM, Vreys I, Deckmyn H, Matthyssens G, Nyström Å, Vermylen J. Characterisation of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo.. Thromb Haemost 1995; 74: 655-9.
• 19 Stassen JM, Nyström Å, Hoylaerts M, Collen D. Antithrombotic effects of thrombolytic agents in a platelet-rich femoral vein thrombosis model in the hamster.. Circulation 1995; 91: 1330-5.
• 20 Gresele P, Arnout J, Deckmyn H, Huybrechts E, Pieters G, Vermylen J. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.. J Clin Invest 1987; 80: 1435-45.
• 21 Falcon C, Arnout J, Vermylen J. Platelet aggregation in whole blood. Studies with a platelet counting technique. Methodological aspects and some applications.. Thromb Haemost 1989; 61: 423-8.
• 22 Deckmyn H, Stanssens P, Hoet B, Declerck PJ, Lauwereys M, Gansemans Y, Tornai I, Vermylen J. An echistatin-like Arg-Gly-Asp (RGD)-containing sequence in the heavy chain CDR3 of a murine monoclonal antibody that inhibits human platelet glycoprotein IIb/IIIa function.. Br J Haematol 1994; 87: 562-71.